<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579383</url>
  </required_header>
  <id_info>
    <org_study_id>ALD403-CLIN-001</org_study_id>
    <nct_id>NCT01579383</nct_id>
  </id_info>
  <brief_title>Safety Tolerability and Pharmacokinetics of ALD403</brief_title>
  <official_title>A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alder Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alder Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics of&#xD;
      ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous&#xD;
      injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ALD403: laboratory variables, ECG and adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physical Examination&#xD;
Vital signs&#xD;
12-lead ECG (electrocardiogram)&#xD;
Clinical laboratory tests (hematology, chemistry)&#xD;
Number of participants with Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pharmacokinetics of ALD403</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cmax - maximum plasma concentration&#xD;
Tmax - Time to achieve maximum plasma concentration&#xD;
AUC - Area under the plasma concentration-time curve&#xD;
T1/2 - Elimination half-life&#xD;
Vz - Volume of distribution&#xD;
CL - Clearance&#xD;
Bioavailability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacodynamics of ALD403</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood perfusion rates&#xD;
Plasma levels of unbound ALD403&#xD;
Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Part A, Cohorts A - H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403/Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403/Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD403/Placebo/Sumatriptan</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD403</intervention_name>
    <description>Single Dose IV infusion on Day 1</description>
    <arm_group_label>Part A, Cohorts A - H</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD403</intervention_name>
    <description>Single Dose subcutaneous injection on Day 1</description>
    <arm_group_label>Part A, Cohort I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Single Dose subcutaneous injection on Day 1</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Part A:&#xD;
&#xD;
          -  Healthy males and females between the ages of 18 and 65 (inclusive).&#xD;
&#xD;
          -  Normal renal function as calculated by the Cockcroft- Gault equation at screening.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to&#xD;
             100kg inclusive.&#xD;
&#xD;
          -  No clinically significant disease or abnormal laboratory values as determined by&#xD;
             medical history, physical examination, electrocardiogram, and laboratory evaluations&#xD;
&#xD;
        Exclusion Criteria Part A:&#xD;
&#xD;
          -  History of febrile illness within 5 days prior to the first dose&#xD;
&#xD;
          -  Any clinically significant laboratory findings&#xD;
&#xD;
          -  Any clinically significant physical exam abnormalities&#xD;
&#xD;
          -  Hospitalization for any reason within 30 days of the screening visit.&#xD;
&#xD;
          -  History of or positive human immunodeficiency virus (HIV) screen result&#xD;
&#xD;
          -  History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C&#xD;
             antibody (HCV) at screening.&#xD;
&#xD;
          -  History of malignancy within five years prior to screening.&#xD;
&#xD;
          -  History of leukemia, myeloproliferative disorder or lymphoproliferative disorder&#xD;
&#xD;
          -  History of rubber, latex allergy or allergy to medical adhesives&#xD;
&#xD;
          -  Positive urine, drug or alcohol screen result&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  Previous treatment or clinical trial with a monoclonal antibody.&#xD;
&#xD;
          -  Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days or at least 5 half-lives&#xD;
&#xD;
        Inclusion Criteria Part B:&#xD;
&#xD;
          -  Healthy females between the ages of 18 and 65 (inclusive).&#xD;
&#xD;
          -  Male and female migraine patients with clinically diagnosed migraine not attributed to&#xD;
             another cause with or without aura based on International Headache Society criteria.&#xD;
&#xD;
          -  Migraine patients must have a history of migraine with or without aura for more than 1&#xD;
             year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to&#xD;
             starting in the study.&#xD;
&#xD;
          -  Normal renal function as defined by Cockcroft- Gault equation at screening.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to&#xD;
             100kg inclusive.&#xD;
&#xD;
          -  No clinically significant disease or abnormal laboratory values as determined by&#xD;
             medical history, physical examination, electrocardiogram, and laboratory evaluations&#xD;
             conducted at the screening visit or at the time of admission&#xD;
&#xD;
        Exclusion Criteria Part B:&#xD;
&#xD;
          -  For migraine patients: patient is not able to refrain from use of their usual triptan&#xD;
             therapy (if applicable) from 48 hours (Day -2) prior to dosing on Day 1 until the&#xD;
             morning of discharge (Day 3).&#xD;
&#xD;
          -  Migraine patients who experience migraine with prolonged aura, familiar hemiplegic&#xD;
             migraine, migrainous infarction or basilar migraine&#xD;
&#xD;
          -  For migraine patients: patient has more than 8 headache-days per month or has taken&#xD;
             medication for acute headache on more than 8 days a month in the past 3 months&#xD;
&#xD;
          -  For migraine patients: patient was greater than 50 years old at the age of migraine&#xD;
             onset&#xD;
&#xD;
          -  History of febrile illness within 5 days prior to the first dose&#xD;
&#xD;
          -  Any clinically significant laboratory findings&#xD;
&#xD;
          -  Any clinically significant physical exam abnormalities&#xD;
&#xD;
          -  Previous treatment or clinical trial with a monoclonal antibody.&#xD;
&#xD;
          -  Hospitalization for any reason within 30 days of the screening visit.&#xD;
&#xD;
          -  History of or positive human immunodeficiency virus (HIV) screen result&#xD;
&#xD;
          -  History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C&#xD;
             antibody (HCV&#xD;
&#xD;
          -  History of malignancy within five years prior to screening.&#xD;
&#xD;
          -  History of leukemia, myeloproliferative disorder or lymphoproliferative disorder&#xD;
&#xD;
          -  Positive urine drug or alcohol screen result&#xD;
&#xD;
          -  Current smokers.&#xD;
&#xD;
          -  Known contraindication to sumatriptan&#xD;
&#xD;
          -  Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days or at least 5 half-lives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hodsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Studies, Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine Disorders</keyword>
  <keyword>Phase 1</keyword>
  <keyword>ALD403</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

